Anticoagulation & Perioperative Management in Mohs Surgery
Current consensus supports continuing anticoagulation and antiplatelet therapy for cutaneous surgery, including Mohs micrographic surgery. The risk of a thromboembolic event from discontinuation (stroke, DVT, PE) far outweighs the manageable risk of surgical bleeding. Studies show discontinuation of warfarin for skin surgery carries a 0.68% thromboembolic event rate, while continuing anticoagulation increases bleeding complication rates by only 2-4% with proper hemostatic technique.
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)·Published: 2026-04-08·Updated: 2026-04-08·Reviewed: 2026-04-08
anticoagulationwarfarindoacantiplateletperioperative managementhemostasisMohs surgerybleeding complications
Key Takeaways
- Continue all anticoagulants and antiplatelet agents for Mohs surgery — discontinuation carries a 0.68% thromboembolic event rate that far exceeds the 2-4% increase in manageable bleeding.
- Check warfarin INR within 72 hours before surgery; proceed if INR is at or below 3.5.
- DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) should be continued without modification; scheduling surgery at the trough level is optional but not required.
- Dual antiplatelet therapy (DAPT) must never be stopped for skin surgery — stent thrombosis from DAPT discontinuation carries 20-40% mortality.
- Meticulous hemostasis with electrocautery, aluminum chloride, suture ligation, and pressure dressings is the cornerstone of safe surgery on anticoagulated patients.
- High-risk patients (DAPT, INR >3.0, scalp/temple procedures, large flaps) should receive pressure dressings for 24-48 hours and an early follow-up wound check.
Overview: Continue Anticoagulation for Cutaneous Surgery
The standard of care for Mohs micrographic surgery and cutaneous surgery is to continue anticoagulation and antiplatelet therapy perioperatively. Multiple professional society guidelines (ACMS, AAD, AHA/ACC) support this approach. The thromboembolic risk from discontinuation is far greater than the bleeding risk from continuation. Discontinuing warfarin for skin surgery carries a thromboembolic event rate of approximately 0.68%, including stroke, pulmonary embolism, and deep vein thrombosis. These events carry significant morbidity and mortality. By contrast, continuing anticoagulation increases postoperative bleeding complications by only 2-4%, and these bleeding events are almost always manageable with local hemostatic measures. The surgeon should plan for increased intraoperative bleeding and employ meticulous hemostasis rather than ask the patient to stop their medication.
Warfarin Management
Warfarin (Coumadin) should be continued for Mohs surgery when the INR is at or below 3.5. The INR should be checked within 72 hours before the procedure to confirm it is in the therapeutic or near-therapeutic range. An INR above 3.0 is associated with incrementally higher bleeding risk, but surgery can proceed safely with enhanced hemostatic measures. An INR above 3.5 warrants discussion with the prescribing physician about temporary dose adjustment (not discontinuation) and rescheduling if the INR cannot be brought into range. Bridging anticoagulation with low-molecular-weight heparin (LMWH) is rarely indicated for skin surgery. Bridging increases both bleeding complications and cost without meaningful reduction in thromboembolic risk for the short operative duration of Mohs procedures.
| INR Range | Recommendation | Bleeding Risk | Action |
|---|---|---|---|
| < 2.0 | Subtherapeutic — proceed with surgery | Lowest | Note subtherapeutic level; no additional measures needed |
| 2.0 - 3.0 | Therapeutic range — proceed with surgery | Mild increase | Standard hemostatic technique; no modification needed |
| 3.0 - 3.5 | Supratherapeutic — proceed with caution | Moderate increase | Enhanced hemostasis; pressure dressings; consider delaying large flaps |
| > 3.5 | Elevated — consider postponing | High | Contact prescribing physician for dose adjustment; reschedule if possible |
Direct Oral Anticoagulants (DOACs)
Direct oral anticoagulants include apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa/Lixiana). All DOACs should be continued for Mohs surgery. Unlike warfarin, DOACs have predictable pharmacokinetics and do not require routine monitoring. Peak anticoagulant effect occurs 1-4 hours after ingestion, and half-lives range from 5-17 hours depending on the agent. Some surgeons schedule the procedure at the trough level (immediately before the next dose), but evidence that this meaningfully reduces bleeding in cutaneous surgery is limited. A practical approach is to proceed with surgery regardless of dosing timing and rely on local hemostasis. Reversal agents exist for dabigatran (idarucizumab) and for factor Xa inhibitors (andexanet alfa), but these are reserved for life-threatening bleeding and are not appropriate for surgical bleeding from skin procedures.
| DOAC | Brand Name | Mechanism | Half-Life | Peak Effect | Reversal Agent |
|---|---|---|---|---|---|
| Apixaban | Eliquis | Factor Xa inhibitor | 8-15 hours | 1-3 hours | Andexanet alfa (life-threatening only) |
| Rivaroxaban | Xarelto | Factor Xa inhibitor | 5-9 hours | 2-4 hours | Andexanet alfa (life-threatening only) |
| Dabigatran | Pradaxa | Direct thrombin inhibitor | 12-17 hours | 1-2 hours | Idarucizumab (Praxbind) |
| Edoxaban | Savaysa / Lixiana | Factor Xa inhibitor | 10-14 hours | 1-2 hours | Andexanet alfa (life-threatening only) |
Antiplatelet Agents
Antiplatelet agents should be continued for Mohs surgery. Aspirin monotherapy has minimal impact on surgical bleeding and should never be stopped for skin surgery. Clopidogrel (Plavix) increases bleeding somewhat more than aspirin alone but should still be continued. Dual antiplatelet therapy (DAPT) — typically aspirin plus clopidogrel, prasugrel (Effient), or ticagrelor (Brilinta) — carries the highest bleeding risk among antiplatelet regimens. DAPT is most often prescribed after coronary stent placement, and premature discontinuation risks acute stent thrombosis, which has a 20-40% mortality rate. The increased surgical bleeding from DAPT is manageable with local hemostatic measures and does not justify the cardiac risk of stopping therapy.
| Agent | Brand Name | Mechanism | Half-Life | Perioperative Recommendation | Relative Bleeding Risk |
|---|---|---|---|---|---|
| Aspirin (low-dose) | Various | COX-1 inhibitor (irreversible) | Platelet lifespan (7-10 days) | Continue — no modification | Low |
| Clopidogrel | Plavix | P2Y12 inhibitor (irreversible) | Platelet lifespan (7-10 days) | Continue — plan for hemostasis | Moderate |
| Prasugrel | Effient | P2Y12 inhibitor (irreversible) | Platelet lifespan (7-10 days) | Continue — higher potency than clopidogrel | Moderate-High |
| Ticagrelor | Brilinta | P2Y12 inhibitor (reversible) | 7-9 hours | Continue — reversible binding | Moderate |
| DAPT (aspirin + P2Y12) | Combination | Dual pathway inhibition | Platelet lifespan | Continue — enhanced hemostasis required | High |
Drug-by-Drug Perioperative Summary
The following table consolidates perioperative recommendations for all commonly encountered anticoagulant and antiplatelet agents in a single reference. The guiding principle across all agents is: continue therapy and manage bleeding locally.
| Drug | Class | Mechanism | Half-Life / Duration | Perioperative Recommendation | Bleeding Risk Level |
|---|---|---|---|---|---|
| Warfarin | Vitamin K antagonist | Clotting factor synthesis inhibition (II, VII, IX, X) | 36-42 hours | Continue if INR ≤ 3.5; check INR within 72 hours pre-op | Moderate (INR-dependent) |
| Apixaban | DOAC — Factor Xa inhibitor | Direct factor Xa inhibition | 8-15 hours | Continue; consider scheduling at trough | Moderate |
| Rivaroxaban | DOAC — Factor Xa inhibitor | Direct factor Xa inhibition | 5-9 hours | Continue; consider scheduling at trough | Moderate |
| Dabigatran | DOAC — Direct thrombin inhibitor | Direct thrombin (factor IIa) inhibition | 12-17 hours | Continue; specific reversal (idarucizumab) available | Moderate |
| Edoxaban | DOAC — Factor Xa inhibitor | Direct factor Xa inhibition | 10-14 hours | Continue; consider scheduling at trough | Moderate |
| Aspirin | Antiplatelet | Irreversible COX-1 inhibition | Platelet lifespan (7-10 days) | Continue — minimal bleeding impact | Low |
| Clopidogrel | Antiplatelet — P2Y12 | Irreversible P2Y12 inhibition | Platelet lifespan (7-10 days) | Continue — plan for local hemostasis | Moderate |
| Prasugrel | Antiplatelet — P2Y12 | Irreversible P2Y12 inhibition | Platelet lifespan (7-10 days) | Continue — more potent than clopidogrel | Moderate-High |
| Ticagrelor | Antiplatelet — P2Y12 | Reversible P2Y12 inhibition | 7-9 hours | Continue — reversible, shorter recovery | Moderate |
| Enoxaparin (LMWH) | Heparin | Antithrombin III potentiation | 4.5-7 hours | Hold morning dose on day of surgery; resume evening | Moderate |
| Heparin (unfractionated) | Heparin | Antithrombin III potentiation | 1-2 hours | Hold infusion 4-6 hours pre-op; resume post-op | Variable |
Hemostasis Techniques for Anticoagulated Patients
Effective hemostasis is the key to safely operating on anticoagulated patients. The surgeon must achieve a completely dry surgical field before wound closure — an incompletely hemostased wound closed under pressure will form a hematoma. Multiple hemostatic techniques should be used in combination, matching the method to the bleeding source.
Electrocoagulation
Electrosurgery is the primary hemostatic tool. Electrocautery (bipolar or monopolar) provides targeted coagulation of bleeding vessels. Bipolar forceps allow precise coagulation of individual vessels with minimal lateral thermal spread. For diffuse oozing in anticoagulated patients, use a broad electrode with light contact in coagulation mode. Avoid excessive charring — char eschar pulls off and re-exposes the vessel.
Chemical Hemostasis
Aluminum chloride (20-35% solution) is the workhorse topical hemostatic agent in dermatologic surgery. It produces vasoconstriction and protein precipitation. Apply with firm pressure using a cotton-tipped applicator directly on the bleeding point. Ferric subsulfate (Monsel solution) is more potent but causes permanent tissue tattooing (iron deposition) and should not be used on the face or cosmetically sensitive areas. Monsel solution can also create histologic artifact that mimics melanin pigment on frozen sections.
Mechanical Methods
Direct pressure for 10-15 minutes with gauze is effective for capillary and small vessel oozing. Suture ligation (tie-off) is required for named arterial vessels that cannot be controlled with electrocautery alone. The angular artery (lateral nose), superficial temporal artery (temple/scalp), and supratrochlear artery (medial forehead) are commonly encountered. Absorbable gelatin sponge (Gelfoam) packed into deep wound cavities provides a scaffold for clot formation. Bone wax controls bleeding from exposed calvarium (diploic veins) during scalp surgery.
Herbal Supplements & Over-the-Counter Agents
Many patients take herbal supplements and over-the-counter agents that may affect platelet function or coagulation. The most commonly encountered include fish oil (omega-3 fatty acids), vitamin E, ginkgo biloba, garlic supplements, and turmeric/curcumin. The clinical evidence that these supplements meaningfully increase surgical bleeding is weak and conflicting. A 2018 systematic review found no statistically significant increase in bleeding complications for patients taking fish oil or vitamin E perioperatively. Current consensus is shifting away from routine preoperative discontinuation of these agents. Most Mohs surgeons no longer require patients to stop fish oil or vitamin E before surgery. Ginkgo and garlic have somewhat stronger evidence of antiplatelet activity in vitro, but the clinical significance during cutaneous surgery remains uncertain.
| Supplement | Proposed Mechanism | Evidence Strength | Current Recommendation |
|---|---|---|---|
| Fish oil (omega-3) | Mild antiplatelet effect; decreased thromboxane A2 | Weak — no significant increase in bleeding shown | Continue; discontinuation not necessary |
| Vitamin E | Inhibits platelet aggregation at high doses | Weak — conflicting data | Continue; discontinuation not necessary |
| Ginkgo biloba | Inhibits platelet-activating factor (PAF) | Moderate — some case reports of bleeding | Consider stopping 7-14 days pre-op if feasible |
| Garlic supplements | Inhibits platelet aggregation, fibrinolysis | Moderate — in vitro effects documented | Consider stopping 7 days pre-op if feasible |
| Turmeric / Curcumin | Inhibits thromboxane and platelet aggregation in vitro | Weak — mostly preclinical data | Continue; clinical significance unproven |
Intraoperative Considerations
Several intraoperative techniques reduce bleeding and improve surgical field visibility in anticoagulated patients. Epinephrine in the local anesthetic (typically 1:100,000 or 1:200,000 concentration) provides vasoconstriction that significantly reduces intraoperative bleeding. Allow 7-10 minutes after injection for full vasoconstrictor effect before incising. Meticulous hemostasis at every layer is required — do not rush to close. Inspect the wound systematically: deep layer first, then wound edges, then the wound surface. Electrocautery each bleeder individually rather than relying on diffuse coagulation. For large flaps and grafts, consider placing a drain (Penrose or closed suction) if the dead space is significant and the patient is on multiple antithrombotic agents.
Postoperative Management
Anticoagulated patients have a higher rate of delayed bleeding and hematoma formation in the first 24-48 hours after surgery. A firm pressure dressing should remain in place for a minimum of 24 hours, and 48 hours for high-risk closures (large flaps, grafts, scalp procedures). Patient education is the most effective tool for managing postoperative bleeding risk. Provide clear written instructions: avoid bending forward, heavy lifting, straining, vigorous exercise, and hot showers for 48 hours. Instruct the patient on applying firm, sustained pressure (20 minutes without releasing) if bleeding occurs at home. Define when to call the office (bleeding not controlled by 20 minutes of pressure, expanding swelling under the wound, fever). Schedule an early follow-up visit at 24-48 hours for high-risk patients (dual antiplatelet therapy, INR >3.0, large flaps) rather than waiting the standard 5-7 days.
Risk Stratification for Bleeding Complications
Not all anticoagulated patients carry the same bleeding risk. Risk stratification before surgery allows the surgeon to allocate additional time, plan hemostatic measures, and schedule appropriate follow-up. Three factors drive bleeding risk: anatomical location, procedure complexity, and the patient's antithrombotic regimen.
High-Risk Anatomical Locations
The scalp and temple carry the highest bleeding risk due to the rich blood supply from the superficial temporal artery, occipital artery, and dense subgaleal vascular plexus. The nose (angular artery, dorsal nasal artery) and ear (superficial temporal branches, posterior auricular artery) are also high-risk locations. The periorbital region bleeds more than expected due to the rich orbital vasculature. Trunk and extremity sites generally have lower bleeding risk.
High-Risk Procedures
Large rotation and transposition flaps create more dead space and more potential for hematoma than primary closures or small advancement flaps. Full-thickness skin grafts require a well-hemostased recipient bed — any bleeding under the graft prevents graft take. Interpolation flaps (paramedian forehead flap, Abbe flap) with their pedicle division at 3 weeks carry bleeding risk at both the initial and second stages. Procedures involving periosteal elevation (scalp flaps with galeal scoring) disrupt the rich subgaleal plexus.
Patient-Level Risk Factors
Dual antiplatelet therapy and combined anticoagulant-antiplatelet regimens (warfarin + aspirin, DOAC + clopidogrel) carry the highest bleeding risk. Supratherapeutic INR (>3.0) on warfarin adds risk. Hepatic dysfunction compounds coagulopathy. Thrombocytopenia (platelet count <100,000) from hematologic conditions or chemotherapy is an independent risk factor. Prior history of postoperative bleeding or hematoma predicts future events.
Frequently Asked Questions
Related Articles
References
- [1]Bordeaux JS, Martires KJ Management of anticoagulation for dermatologic procedures. Dermatol Ther. 2015.
- [2]Callahan S, Goldsberry A, Kim G, Yoo S The management of antithrombotic medication in skin surgery. Dermatol Surg. 2014.
- [3]McCrae SE, Stasko T Direct oral anticoagulants in cutaneous surgery: a review. J Am Acad Dermatol. 2021.
- [4]Kovich O, Otley CC Perioperative management of anticoagulants and antiplatelet agents. Semin Cutan Med Surg. 2012.
- [5]Tucker WO, Chau CH Antiplatelet agents in dermatologic surgery. Dermatol Surg. 2018.
- [6]Iyengar S, Yeong EK Hemostasis in dermatologic surgery: techniques and agents. J Cutan Med Surg. 2020.